Core Viewpoint - Moderna Inc. has resolved a four-year legal dispute regarding patent infringement related to its lipid nanoparticle (LNP) delivery technology, resulting in a significant stock price increase of 15.99% to $57.80 [1]. Group 1: Legal Settlement Details - Moderna has agreed to pay a total of $2.5 billion to Arbutus Biopharma Corporation and Genevant Sciences GmbH to settle the LNP patent infringement case, with $950 million to be paid as a lump sum in Q3 and the remaining $1.3 billion contingent on the outcome of its appeal [2]. - The legal issue involved allegations that Moderna used Arbutus and Genevant's LNP technology for its Spikevax and mRESVIA vaccines without permission [4]. - If Moderna prevails in its appeal, no further payments will be required; however, if liability is affirmed, an additional payment of up to $1.3 billion will be due within 90 days of the decision [5]. Group 2: Financial Implications - Moderna expects to record charges of $950 million in the first quarter related to the settlement and anticipates ending the year with cash and cash equivalents between $4.5 billion and $5 billion [6].